Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.
Fundamental & clinical pharmacology, cilt.35, ss.62-75, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 35
- Basım Tarihi: 2021
- Doi Numarası: 10.1111/fcp.12589
- Dergi Adı: Fundamental & clinical pharmacology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
- Sayfa Sayıları: ss.62-75
- Anahtar Kelimeler: melatonin, COVID-19, renin-angiotensin system, antioxidant, anti-inflammatory, immunomodulatory, ISCHEMIA-REPERFUSION INJURY, OXIDATIVE STRESS, PROGRAMMED HYPERTENSION, ACTIVATION, PROTECTS, HYDROXYCHLOROQUINE, EXPRESSION, INFECTION, APOPTOSIS, EFFICACY
- İnönü Üniversitesi Adresli: Evet
Özet
Coronavirus disease 2019 (COVID-19) is a life-threatening infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 pandemic causing morbidities and even deaths worldwide revealed that there is urgent need to find pharmacological agents or vaccines. Although there are a lot of agents under investigation, there is no approved agent for the prevention or treatment of the COVID-19 yet. Treatment of patients remains mainly supportive as well as compassionate use of the agents under investigation. It is well established that excessive inflammatory and immune response and oxidative injury play a critical role in the pathogenesis of COVID-19. In this review, we aimed to update knowledge about pathogenesis, clinical features, and pharmacological treatment of COVID-19 and review the potential beneficial effects of ancient antioxidant, anti-inflammatory, and immunomodulatory molecule melatonin for prevention and treatment of COVID-19.